Cullinan Therapeutics (CGEM) Operating Leases (2022 - 2026)

Cullinan Therapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Operating Leases rose 236.31% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 236.31% YoY), while the FY2025 annual figure was $1.9 million, up 124.15% from the prior year.
• Operating Leases for Q1 2026 stood at $1.7 million, down from $1.9 million in the prior quarter.
• The five-year high for Operating Leases was $4.0 million in Q3 2022, with the low at $125000.0 in Q2 2025.
• The 5-year median for Operating Leases is $1.7 million (2024), against an average of $1.8 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases jumped 358.72% in 2023, then tumbled 91.77% in 2025.
• Cullinan Therapeutics' Operating Leases stood at $3.6 million in 2022, then tumbled by 40.11% to $2.2 million in 2023, then tumbled by 60.51% to $849000.0 in 2024, then soared by 124.15% to $1.9 million in 2025, then decreased by 12.87% to $1.7 million in 2026.
• Business Quant data shows CGEM's Operating Leases at $1.7 million in Q1 2026, $1.9 million in Q4 2025, and $125000.0 in Q2 2025.